Who are Carminomicin I's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zinecard, Idamycin Pfs, Vepesid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/carubicin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Carminomicin I — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Carminomicin I (CARUBICIN) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: carubicin. Area: Other.

phase 2 carubicin DNA topoisomerase 2-alpha Other Small molecule Live · refreshed every 30 min

Target snapshot

Carminomicin I (CARUBICIN). CARUBICIN works by binding to DNA topoisomerase 2-alpha, preventing the enzyme from unwinding DNA and leading to cell death.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Carminomicin I TARGET	CARUBICIN		phase 2	carubicin	DNA topoisomerase 2-alpha
Zinecard	DEXRAZOXANE	Pfizer	marketed	Cytoprotective Agent	DNA topoisomerase 2-alpha	1995-01-01
Idamycin Pfs	IDARUBICIN		marketed	Anthracycline Topoisomerase Inhibitor	DNA topoisomerase 2-alpha	1990-01-01
Vepesid	etoposide	Bristol-Myers Squibb K.K.	marketed	Topoisomerase Inhibitor [EPC]	DNA topoisomerase 2-alpha	1983-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (carubicin class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Carminomicin I — Competitive Intelligence Brief. https://druglandscape.com/ci/carubicin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing